[Skip to Navigation]
March 1992

Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccine in Children With Sickle Cell Disease

Author Affiliations

From the Department of Pediatrics, Schneider Children's Hospital of Long Island Jewish Medical Center, New Hyde Park, NY.

Am J Dis Child. 1992;146(3):340-342. doi:10.1001/archpedi.1992.02160150080026

• Objective.  —To determine the safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease.

Research Design.  —Prospective, nonrandomized, nonblinded study.

Setting.  —Hospital-based, comprehensive sickle cell center.

Patients.  —Children with sickle cell disease aged 18 months to 18 years who were previously unvaccinated or had an inadequate or waning response to H influenzae type b polysaccharide vaccine.

Selection Procedures.  —Consecutive eligible patients.

Interventions.  —Vaccination and observation for adverse effects. Blood samples were taken before and 1 to 2 and 6 months after vaccination to measure anticapsular antibody levels.

Measurements and Results.  —Vaccination was well tolerated. One hundred percent and 96% of the 31 immunized children had postvaccination anticapsular antibody concentrations of greater than 0.15 and 1.0 mg/L, respectively. Six months after vaccination, 100% and 89% of children had these antibody concentrations.

Conclusions.  H influenzae type b conjugate vaccines are safe and highly immunogenic in children with sickle cell disease. It is likely that these vaccines will be protective against invasive H influenzae type b disease.(AJDC. 1992;146:340-342)

Add or change institution